Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Moleculin Biotech (MBRX) Interest & Investment Income (2022 - 2025)

Moleculin Biotech's Interest & Investment Income history spans 4 years, with the latest figure at $9000.0 for Q4 2025.

  • Quarterly results put Interest & Investment Income at $9000.0 for Q4 2025, down 80.85% from a year ago — trailing twelve months through Dec 2025 was $104000.0 (down 81.06% YoY), and the annual figure for FY2025 was $105000.0, down 80.91%.
  • Interest & Investment Income for Q4 2025 was $9000.0 at Moleculin Biotech, down from $39000.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $392000.0 in Q1 2023 to a low of $9000.0 in Q4 2025.
  • The 4-year median for Interest & Investment Income is $74500.0 (2024), against an average of $141312.5.
  • The sharpest move saw Interest & Investment Income soared 900.0% in 2023, then plummeted 87.55% in 2025.
  • Year by year, Interest & Investment Income stood at $126000.0 in 2022, then surged by 107.94% to $262000.0 in 2023, then tumbled by 82.06% to $47000.0 in 2024, then crashed by 80.85% to $9000.0 in 2025.
  • According to Business Quant data, Interest & Investment Income over the past three periods came in at $9000.0, $39000.0, and $26000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.